跳至主要内容
临床试验/ACTRN12605000521628
ACTRN12605000521628已完成不适用

A phase I study to compare the steady-state pharmacokinetics of estradiol following application to the abdomen of an Estradiol Metered-Dose Transdermal Spray (MDTS) and Estraderm 50 patches in healthy postmenopausal women, as hormone replacement therapy.

FemPharm Pty Ltd and/or Acrux DDS Pty Ltd0 个研究点目标入组 18 人开始时间: 2005年9月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 ot stated(—)
性别
Female

入选标准

  • Healthy post-menopausal women

排除标准

  • No exclusion criteria

研究者

发起方
FemPharm Pty Ltd and/or Acrux DDS Pty Ltd

相似试验

已完成
不适用
A study to evaluate the pharmacokinetic and pharmacodynamic equivalence of HSP-130 and United States-approved Neulasta (Registered Trademark) and European Union-approved Neulasta (Registered Trademark) administered as a single subcutaneous dose to healthy volunteers.The study will be conducted in healthy subjects. Neulasta is indicated for the treatment of cancer chemotherapy-induced neutropenia.Cancer - Any cancer
ACTRN12615001049561Hospira, Inc.150
已完成
不适用
A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects.Blooddiseaseleukemia/lymophoma10047954
NL-OMON35094Calistoga Pharmaceuticals Inc.15
招募中
不适用
Pharmacological study of chronomodulated capecitabine therapycancer, capecitabine, phase I, chronotherapy, biomarker, pharmacology, kanker, chronotherapie, fase I
NL-OMON24089etherlands Cancer Institute - Antoni van Leeuwenhoek Hospital42
招募中
不适用
Phase I pharmacological study of continuous and intermittent chronomodulated capecitabine therapymalignancies10027655cancer
NL-OMON40756Antoni van Leeuwenhoek Ziekenhuis42
已完成
1 期
An interventional study to evaluate the effects of formulation and dose on the Pharmacokinetics (PK, the measure of how the human body prcessed a substance) of up to four Donezepil Transdermal Delivery System (TDS, a patch that delivers a drug) formulations (50 cm2 patch size), worn for seven days, applied to the backs of healthy female participants.Alzheimer’s DiseaseNeurological - Alzheimer's disease
ACTRN12616000348459INCResearch Australia Pty Ltd24